Mega Lifesciences PCL (BKK:MEGA-R) EBIT : ฿2,379 Mil (TTM As of Mar. 2025)

View and export this data going back to 2013. Start your Free Trial

What is Mega Lifesciences PCL EBIT?

Mega Lifesciences PCL's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2025 was ฿542 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2025 was ฿2,379 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Mega Lifesciences PCL's annualized ROC % for the quarter that ended in Mar. 2025 was 28.78%. Mega Lifesciences PCL's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was 44.51%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Mega Lifesciences PCL's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was 11.22%.

Mega Lifesciences PCL EBIT Historical Data

The historical data trend for Mega Lifesciences PCL's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mega Lifesciences PCL EBIT Chart

Mega Lifesciences PCL Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EBIT

Get a 7-Day Free Trial

1,695.05

2,305.16

2,623.41

2,292.93

2,390.68

Mega Lifesciences PCL Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EBIT	Get a 7-Day Free Trial															553.61	615.34	465.88	755.85	541.94

Competitive Comparison of Mega Lifesciences PCL's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Mega Lifesciences PCL's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mega Lifesciences PCL's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mega Lifesciences PCL's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Mega Lifesciences PCL's EV-to-EBIT falls into.

Save Embed

;

Save Embed

;

Mega Lifesciences PCL EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿2,379 Mil.

Mega Lifesciences PCL (BKK:MEGA-R) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Mega Lifesciences PCL's annualized ROC % for the quarter that ended in Mar. 2025 is calculated as:

	ROC % (Q: Mar. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2024 )	+	Invested Capital (Q: Mar. 2025 ))	/ count )
=	2439.216 * ( 1 - 15.59% )	/	( (7009.382	+	7297.302)	/ 2 )
=	2058.9422256	/	7153.342
=	28.78 %

where

	Invested Capital		(Q: Dec. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	14210.134	-	3387.723	-	( 3813.029	-	max(0, 3914.314	-	10226.694	+	3813.029	))
=	7009.382

	Invested Capital		(Q: Mar. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	14364.102	-	3157.63	-	( 3909.17	-	max(0, 3610.552	-	10149.643	+	3909.17	))
=	7297.302

Note: The Operating Income data used here is four times the quarterly (Mar. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Mega Lifesciences PCL's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2025 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2024		Q: Mar. 2025
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	2167.768	/	( ( (2212.922 + max(2698.242, 0))	+	(2220.052 + max(2609.323, 0)) )	/	2 )
=	2167.768	/	( ( 4911.164	+	4829.375 )	/	2 )
=	2167.768	/	4870.2695
=	44.51 %

where Working Capital is:

	Working Capital		(Q: Dec. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(2975.207	+	3032.904	+	253.028)	-	(3387.723	+	54.01	+	121.164)
=	2698.242

	Working Capital		(Q: Mar. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(2764.485	+	3004.293	+	120.339)	-	(3157.63	+	0	+	122.164)
=	2609.323

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Mega Lifesciences PCL's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2025 )
	=	2379.01	/	21198.380
	=	11.22 %

Mega Lifesciences PCL EBIT Related Terms

Thank you for viewing the detailed overview of Mega Lifesciences PCL's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Mega Lifesciences PCL Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mega Lifesciences PCL (BKK:MEGA-R) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

MEGA:Thailand

Address

Debaratna Road, 909, Ample Tower, 9th Floor, Bangna Nuea, Bangna, Bangkok, THA, 10260

Website

https://www.megawecare.com

Mega Lifesciences PCL manufactures and sells through independent distributors of health food supplements, branded prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods as well as provides distribution services relating to such products. The company's product portfolio consists of health food supplements, branded prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods. Its segments include Brands in which goods are manufactured and sold under brands owned by the group; Distribution in which the group provides logistical and marketing services for goods trading purposes and sale of goods manufactured by third parties; and OEM.

Mega Lifesciences PCL Headlines

No Headlines